Ozmosi | Daraxonrasib Drug Profile

Product Description

RMC-6236 is a potent, orally bioavailable RAS-MULTI(ON) inhibitor, selective for the active RAS(ON) form of both wild type and mutant variants of the canonical RAS isoforms (HRAS, NRAS, and KRAS). (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT05379985)

Mechanisms of Action: RAS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Pancreatic Cancer
Orphan Drug - Pancreatic Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Revolution Medicines
Company Location: Western America
Company Founding Year: 2014
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Daraxonrasib

Countries in Clinic: Australia, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hong Kong, Ireland, Italy, Japan, Netherlands, New Zealand, Poland, Puerto Rico, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 15

Recent & Upcoming Milestones

Clinical Outcomes Reported - Tango Therapeutics presented P1 Pancreatic Ductal Carcinoma|Non-Small-Cell Lung Cancer results on 2026-06-08 for Daraxonrasib
Clinical Outcomes Expected - Tango Therapeutics announced they will present P1 Pancreatic Cancer|Lung Cancer results in YE26 for Daraxonrasib
Clinical Outcomes Reported - Revolution Medicines presented P3 Pancreatic Cancer results on 2026-05-29 for Daraxonrasib

Highest Development Phases

Phase 3: Adenocarcinoma|Carcinoma, Adenosquamous|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06625320	RASolute 302	P3	Active, not recruiting	Pancreatic Ductal Carcinoma\|Adenocarcinoma\|Pancreatic Cancer	2026-06-01	50%	2026-04-28	Patient Enrollment\|Primary Endpoints
NCT05379985	RMC-6236-001	P2	Recruiting	Non-Small-Cell Lung Cancer\|Colorectal Cancer\|Melanoma\|Thoracic Cancer\|Gastrointestinal Cancer\|Pancreatic Cancer\|Adenocarcinoma\|Pancreatic Ductal Carcinoma	2027-05-31	12%	2025-11-13	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT06128551	RMC-6291-101	P2	Recruiting	Appendiceal Cancer\|Thoracic Cancer\|Pancreatic Ductal Carcinoma\|Non-Small-Cell Lung Cancer\|Intestinal Diseases\|Ovarian Diseases\|Rectal Diseases\|Colorectal Cancer\|Stomach Diseases\|Bronchial Cancer\|Ovarian Cancer\|Endometrial Cancer\|Adenocarcinoma\|Respiratory Tract Cancer\|Colonic Diseases\|Esophageal Diseases\|Gastrointestinal Cancer\|Esophageal Cancer\|Pancreatic Cancer	2028-12-01	12%	2026-02-12
NCT07491445	RASolute 303	P3	Recruiting	Carcinoma, Adenosquamous\|Pancreatic Ductal Carcinoma\|Pancreatic Cancer\|Adenocarcinoma	2028-06-01	50%	2026-03-25	Primary Endpoints\|Treatments
2023-509572-42-00	RMC-LUNG-101B	P1	Recruiting	Lung Cancer	2026-01-30		2025-05-02	Treatments
jRCT2031250809	jRCT2031250809	P3	Not yet recruiting	Adenocarcinoma\|Pancreatic Ductal Carcinoma\|Pancreatic Cancer	2030-07-10
2025-523495-23-00	RMC-6236-304	P3	Not yet recruiting	Pancreatic Cancer\|Pancreatic Ductal Carcinoma\|Adenocarcinoma	2030-07-10
NCT07252232	RASolute 304	P3	Recruiting	Adenocarcinoma\|Pancreatic Cancer\|Pancreatic Ductal Carcinoma	2029-05-10	16%	2026-04-07	Primary Endpoints\|Start Date\|Treatments
jRCT2031240614	jRCT2031240614	P3	Not yet recruiting	Pancreatic Cancer\|Pancreatic Ductal Carcinoma\|Adenocarcinoma	2027-12-31
2024-516063-89-00	RMC-6236-302	P3	Recruiting	Pancreatic Cancer\|Adenocarcinoma\|Pancreatic Ductal Carcinoma	2027-12-30		2025-05-02	Treatments
NCT06881784	RASolve 301	P3	Recruiting	Non-Small-Cell Lung Cancer	2027-12-01	14%	2026-05-30
2023-509571-16-00	RMC-LUNG-101A	P1	Recruiting	Lung Cancer	2027-06-30		2025-05-02	Treatments
2025-521147-21-00	RMC-LUNG-101C	P2	Not yet recruiting	Lung Cancer	2027-02-26
2024-518154-16-00	RMC-6236-301	P3	Not yet recruiting	Non-Small-Cell Lung Cancer	2030-12-01
jRCT2031250204	jRCT2031250204	P3	Not yet recruiting	Non-Small-Cell Lung Cancer	2030-12-01

Recent News Events

Date	Type	Title
04/21/2026	News Article	Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
04/21/2026	News Article	Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
04/21/2026	News Article	Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
04/17/2026	News Article	Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Daraxonrasib

Alternative Names: Daraxonrasib, rmc-6236, rmc 6236, rmc6236 Clinical Status: Active Latest Update: 2026-06-03 Latest Update Note: Clinical Trial Update